Compass Pathways Plc ADR (CMPS) Stock Price, Quote & News

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incor...

Industry: Medical Care Facilities

Sector: Healthcare

Website: compasspathways.com

Address:

33 Broadwick Street, London, United Kingdom

thenewmoney Jan. 17 at 8:28 PM

Billionaire Christian Angermayer is one of the world’s most prolific entrepreneurs and investors in technology and biotech. And his psychedelic drug development company is on a mission to be on the leading edge of the psychedelic medicine revolution in America. $ATAI $CMPS https://www.thenew.money/article/christian-angermayers-ataibeckley-is-all-in-on-pyschedelic-medicines-in-america

0 · Reply

Mastacash Jan. 17 at 5:39 PM

$HELP, $ATAI, $MNMD, $CMPS, $GHRS. Check out my article on Psychedelics. We are just at the beginning. https://x.com/mastacash/status/2012560389712511287?s=12&t=jCHCXrWm93J_2H0pU9P1Fw

0 · Reply

Stoneape Jan. 17 at 2:30 AM

$CMPS This is easily a 2 billion dollar company. East double from these prices IMO

0 · Reply

BobJohnBuoy666 Jan. 16 at 8:13 PM

$CMPS still consolidating within bearish wedge, maintaining neutral outlook short term

0 · Reply

cacci11 Jan. 16 at 5:53 PM

$CMPS what the heck was that PM blip to $8??

0 · Reply

zmanx Jan. 16 at 1:23 AM

$CMPS looks like a nice year ahead. Strong hold…

0 · Reply

macrossluvsrobotech Jan. 15 at 9:45 PM

$CMPS Will be the first to market. RFK Jr, will unleash this. Topline will be good. Topline in June was EXCELLENT. IT WORKS. All this pending phase 3 comp006 will tell us is dosing. RFK Jr will greenlight this so godamn fast. That event in January, the commercialization. Radial putting in their own money to get the offcices ready. The Hercules Loan, assuring solid 2026-2027 supply of liquidity, with ZERO need for more money. I don't understand why anybody here would even fathom a 6 dollar and change entry here. It's not going to happen. IF YOU WANT TO KNOW WHAT'S GOING TO HAPPEN IN THE NEAR FUTURE UNDE THIS ADMINISTATION? JUST WATCH THE FOLLOWING VIDEO, AND ASK YOURSELF WHO HEADS THE FDA NOW. https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ $ATAI $MNMD $IBB $BIB

2 · Reply

Stoneape Jan. 15 at 9:19 PM

$CMPS dont play around. This is about to go

1 · Reply

macrossluvsrobotech Jan. 15 at 9:10 PM

$CMPS Good luck. lol... 6...

0 · Reply

FBP Jan. 15 at 9:02 PM

$CMPS come to 6s again and I'll re-enter. Missed that lucky 5 re-entry in december but pdufa is getting closer so I'lll take 6 for a 10 pdufa approval

0 · Reply

Compass Pathways: Exciting Prospects For This Psychedelic Pioneer With Significant Risks

Jan 7, 2026, 5:07 PM EST - 10 days ago

COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript

Jan 7, 2026, 6:30 AM EST - 10 days ago

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Jan 6, 2026, 6:30 AM EST - 11 days ago

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Dec 9, 2025, 6:30 AM EST - 5 weeks ago

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Nov 20, 2025, 6:30 AM EST - 2 months ago

Compass Pathways to Participate in Two Investor Conferences in December

Nov 5, 2025, 6:30 AM EST - 2 months ago

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 11:16 AM EST - 2 months ago

COMPASS Pathways plc (CMPS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 6:45 AM EST - 2 months ago

Compass Pathways to expedite launch timing of its experimental depression therapy

Nov 4, 2025, 6:30 AM EST - 2 months ago

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Oct 30, 2025, 8:30 AM EDT - 2 months ago

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Oct 29, 2025, 6:30 AM EDT - 2 months ago

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Oct 28, 2025, 6:30 AM EDT - 2 months ago

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Sep 9, 2025, 2:03 PM EDT - 4 months ago

COMPASS Pathways Plc (CMPS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 4, 2025, 4:56 AM EDT - 4 months ago

COMPASS Pathways Plc (CMPS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 2, 2025, 6:30 AM EDT - 4 months ago

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Aug 27, 2025, 6:30 AM EDT - 5 months ago

Compass Pathways to Participate in Four Investor Conferences in September

Aug 5, 2025, 6:30 AM EDT - 5 months ago

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Jul 31, 2025, 10:32 AM EDT - 6 months ago

COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:30 AM EDT - 6 months ago

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Jul 29, 2025, 6:30 AM EDT - 6 months ago

Compass Pathways Appoints Justin Gover to Board of Directors

Jul 22, 2025, 6:30 AM EDT - 6 months ago

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Jul 10, 2025, 4:00 PM EDT - 6 months ago

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Jun 24, 2025, 2:47 PM EDT - 7 months ago

Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360

Jun 23, 2025, 8:25 AM EDT - 7 months ago

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

VZLA

Jun 23, 2025, 8:12 AM EDT - 7 months ago

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Jun 23, 2025, 6:48 AM EDT - 7 months ago

Compass Pathways' depression drug succeeds late-stage trial

Jun 23, 2025, 6:30 AM EDT - 7 months ago

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

May 14, 2025, 6:30 AM EDT - 8 months ago

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 11:14 AM EDT - 9 months ago

COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Apr 28, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Apr 22, 2025, 6:00 AM EDT - 9 months ago

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Mar 28, 2025, 5:01 PM EDT - 10 months ago

This Is a Test From GlobeNewswire

ALVO

Mar 26, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Mar 18, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Mar 11, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways to Participate in Stifel Virtual CNS Forum

Feb 28, 2025, 5:08 PM EST - 11 months ago

Compass Pathways: Betting On The Future Of Psilocybin Therapy

Feb 27, 2025, 4:02 PM EST - 11 months ago

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says

Feb 27, 2025, 10:41 AM EST - 11 months ago

COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:30 AM EST - 11 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Feb 25, 2025, 4:00 PM EST - 11 months ago

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 6:30 AM EST - 11 months ago

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Feb 5, 2025, 6:30 AM EST - 1 year ago

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 6:30 AM EST - 1 year ago

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Jan 10, 2025, 7:01 AM EST - 1 year ago

Compass Pathways Announces Pricing of Underwritten Offering

Dec 18, 2024, 6:30 AM EST - 1 year ago

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Nov 25, 2024, 4:00 PM EST - 1 year ago

Compass Pathways to Participate in December Investor Conferences

Nov 14, 2024, 7:44 AM EST - 1 year ago

Compass Pathways to participate in Stifel 2024 Healthcare Conference

thenewmoney Jan. 17 at 8:28 PM

0 · Reply

Mastacash Jan. 17 at 5:39 PM

$HELP, $ATAI, $MNMD, $CMPS, $GHRS. Check out my article on Psychedelics. We are just at the beginning. https://x.com/mastacash/status/2012560389712511287?s=12&t=jCHCXrWm93J_2H0pU9P1Fw

0 · Reply

Stoneape Jan. 17 at 2:30 AM

$CMPS This is easily a 2 billion dollar company. East double from these prices IMO

0 · Reply

BobJohnBuoy666 Jan. 16 at 8:13 PM

$CMPS still consolidating within bearish wedge, maintaining neutral outlook short term

0 · Reply

cacci11 Jan. 16 at 5:53 PM

$CMPS what the heck was that PM blip to $8??

0 · Reply

zmanx Jan. 16 at 1:23 AM

$CMPS looks like a nice year ahead. Strong hold…

0 · Reply

macrossluvsrobotech Jan. 15 at 9:45 PM

2 · Reply

Stoneape Jan. 15 at 9:19 PM

$CMPS dont play around. This is about to go

1 · Reply

macrossluvsrobotech Jan. 15 at 9:10 PM

$CMPS Good luck. lol... 6...

0 · Reply

FBP Jan. 15 at 9:02 PM

$CMPS come to 6s again and I'll re-enter. Missed that lucky 5 re-entry in december but pdufa is getting closer so I'lll take 6 for a 10 pdufa approval

0 · Reply

macrossluvsrobotech Jan. 15 at 6:12 PM

$CMPS Keep selling into topline. I'll take all your shares...

0 · Reply

macrossluvsrobotech Jan. 15 at 4:00 PM

$CMPS I only follow the King of the FDA = https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ

0 · Reply

BobJohnBuoy666 Jan. 15 at 2:57 PM

$HELP $CMPS go look at order flow distribution and you will see an unusual number of medium sized inflows...somethings up

1 · Reply

Mastacash Jan. 15 at 5:01 AM

$HELP Broke out of the 2 year long downtrend, retested and bounced of the trendline and 200dma. Consolidation here would be welcome, it will set up a monster move soon. 🚀 I can’t find a better catch up trade in the market. Peers $MNMD $ATAI $GHRS $CMPS all with billion dollar or more market caps. $HELP is going to 3x in a hurry.

1 · Reply

stoxx0007 Jan. 15 at 12:49 AM

$ATAI $MNMD $HELP $CMPS $PSIL DOMAIN FOR SALE!!!

0 · Reply

Bbbb44444 Jan. 15 at 12:07 AM

$CMPS $GHRS $ATAI JFC. This entire admin is a bunch of retarded chaos agents. https://apple.news/Al_h29C6mTMi_6aq-plmcbw

0 · Reply

macrossluvsrobotech Jan. 14 at 5:14 PM

$BIB $CMPS $IBB $MNMD $SNDL DEA WOULD BE FORECED TO RECLASSIFY PSILOCYBIN (ONLY THE $CMPS VERSION APPROVED BY THE FDA, IT WOULD NOT BE A GENERAL RECLASSIFICATION) = AFTER FDA APPROVAL AWAY FROM CLASS 1. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana&#39;s ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $MNMD

1 · Reply

macrossluvsrobotech Jan. 14 at 5:09 PM

$CMPS $SNDL $CMPS Q1 2026 pending phase 3 topline imminent for COMP 360. I wonder why.. "RUMOR: 🇺🇸 President Trump is considering reclassifying psychedelics as a less harmful drug class." Maybe this is the reason = "COMPASS or others) is the most direct federal route to enabling prescription access. There's also a separate ongoing petition to reschedule psilocybin broadly, advanced by DEA to HHS review in 2025, but that's independent. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $MNMD

0 · Reply

brodobagginz Jan. 14 at 3:12 PM

$CMPS spicy action today

0 · Reply

a_rational_investor Jan. 14 at 3:01 PM

$CMPS so we’re just going to stay at 7.37 all day

0 · Reply

macrossluvsrobotech Jan. 13 at 4:42 PM

$CMPS Watch this, and pay close attention to the DATE of when RFK Jr is sitting at a congressional hearing and pay VERY CLOSE ATTENTION TO WHAT HE SAYS, THIS IS COMING FROM THE TOP OF THE FDA, THE BRASS, THE DECISION MAKERS, THE SHIP STEERERS. https://youtu.be/4V7C_bdsu1Q?si=VRYpS5_k435ndpVI

0 · Reply

macrossluvsrobotech Jan. 13 at 4:37 PM

$CMPS Aside from RFK Jr being a MAJOR proponent of psilocybin treatment, is not head of the FDA we have the political winds at our backs: midterms. Trump needs the left from center Independent vote, he's already got the Latino vote in the bag with Maduro pissing himself in Jail. Pam is working on classification UNDER EXECUTIVE ORDER of Cannabis to classification 3. Dems and Republicans want to seem squares, and also want the vote, so they'll all glide the classification to 3 easily. News is, it's got bipartisan support. This will be the first approved at the federal level Psilocybin treatment on the market.

0 · Reply

Market Cap	705.73M
Revenue (ttm)	0.00
Net Income (ttm)	-155.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.83

Volume	748,700
Avg Vol	1,494,914
Day's Range	N/A - N/A
Shares Out	96.02M
Stochastic %K	48%
Beta	1.92
Analysts	Strong Sell
Price Target	$16.82